Simeon Allan
About Simeon Allan
Simeon Allan is the Vice President, Head of Global Development Operations at BMS Hyderabad, with extensive experience in clinical trial strategy and operations across multiple regions.
Current Title
Simeon Allan is currently the Vice President, Head of Global Development Operations at BMS Hyderabad. Based in Hyderabad, Telangana, India, he leads the global development operations for Bristol Myers Squibb.
Previous Roles at BMS
Simeon Allan has held several key positions at Bristol Myers Squibb. From 2020 to 2023, he was Vice President, Clinical Trial Strategy & Operations in the New York City Metropolitan Area. Prior to this, he served as Executive Director, Head of Clinical Operations, APAC from 2018 to 2020 in Tokyo, Japan.
Career at Parexel and UCB
Before joining Bristol Myers Squibb, Simeon Allan worked at Parexel as Vice President, Head of Japan Clinical Operations from 2015 to 2018. Prior to that, he held various leadership roles at UCB, including Director, Head of Clinical Operations Management, East Asia, and Associate Director, Development Operations & Clinical Project Management in Tokyo, Japan.
Early Career in Clinical Research
Simeon Allan began his career in clinical research with roles such as Clinical Research Associate at Warner Lambert and Clinical Data Monitor at The Wellcome Foundation Limited. He also worked at Glaxo Laboratories as a Clinical Research Scientist and at COVANCE CLINICAL AND PERIAPPROVAL SERVICES LIMITED as Principal CRA / Clinical Project Manager.
Educational Background
Simeon Allan studied at the University of Portsmouth where he earned a Bachelor of Science degree in Biology/Biological Sciences. Additionally, he attended Kai Japanese Language School in Tokyo, Japan, where he completed an Advanced Japanese Language Certification.
Professional Expertise in Clinical Operations
Simeon Allan has extensive experience in leading integrated global development operations teams. He has been accountable for delivering clinical trials and innovative digital capabilities across multiple therapeutic areas and phases. He has a proven track record of building new and enhanced capabilities, managing multi-disciplinary teams, and fostering team spirit to meet scientific and business objectives.